Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

Area of Science:

• Infectious Diseases
• Gastroenterology
• Pharmacology

Background:

• Clostridium difficile infection (CDI) is a leading cause of infectious diarrhea in hospitalized patients.
• Recurrences of CDI are frequent following antibiotic treatment.
• Monoclonal antibodies actoxumab and bezlotoxumab target C. difficile toxins A and B, respectively.

Purpose of the Study:

• To evaluate the efficacy and safety of bezlotoxumab, alone or in combination with actoxumab, in preventing recurrent C. difficile infection.
• To assess the impact of these therapies on initial and sustained clinical cure rates.
• To compare the safety profiles of bezlotoxumab and actoxumab plus bezlotoxumab against placebo.

Main Methods:

• Two randomized, double-blind, placebo-controlled phase 3 trials (MODIFY I and MODIFY II) were conducted.
• 2655 adults with primary or recurrent C. difficile infection received standard-of-care antibiotics plus infusions of bezlotoxumab, actoxumab plus bezlotoxumab, or placebo.
• The primary endpoint was recurrent infection within 12 weeks post-infusion.

Main Results:

• Bezlotoxumab significantly lowered the rate of recurrent C. difficile infection compared to placebo in both trials (17% vs. 28% and 16% vs. 26%).
• Actoxumab plus bezlotoxumab also showed significantly lower recurrence rates than placebo (16% vs. 28% and 15% vs. 26%).
• Sustained cure rates were higher with bezlotoxumab (64%) and actoxumab plus bezlotoxumab (58%) compared to placebo (54%); adverse event rates were similar across groups.

Conclusions:

• Bezlotoxumab monotherapy was associated with a substantially lower rate of recurrent C. difficile infection and a comparable safety profile to placebo.
• The addition of actoxumab to bezlotoxumab did not provide additional efficacy benefits.
• Bezlotoxumab represents a promising therapeutic strategy for reducing CDI recurrence in patients undergoing antibiotic treatment.